|
🐜
|
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
24 auth.
R. Stupp,
M. Hegi,
W. Mason,
M. J. van den Bent,
M. Taphoorn,
R. Janzer,
S. Ludwin,
A. Allgeier,
B. Fisher,
K. Bélanger,
...
P. Hau,
A. Brandes,
J. Gijtenbeek,
C. Marosi,
C. Vecht,
K. Mokhtari,
P. Wesseling,
S. Villà,
E. Eisenhauer,
T. Gorlia,
M. Weller,
D. Lacombe,
J. Cairncross,
R. Mirimanoff
|
12 |
2009 |
12
🐜
|
|
🐜
|
MGMT gene silencing and benefit from temozolomide in glioblastoma.
17 auth.
M. Hegi,
A. Diserens,
T. Gorlia,
M. Hamou,
N. Tribolet,
N. Tribolet,
M. Weller,
J. Kros,
J. Hainfellner,
W. Mason,
...
L. Mariani,
Jacoline E. C. Bromberg,
P. Hau,
R. Mirimanoff,
J. Cairncross,
R. Janzer,
R. Stupp
|
12 |
2005 |
12
🐜
|
|
🐜
|
Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma
15 auth.
J. Dalmau,
E. Tüzün,
Hai‐yan Wu,
J. Masjuán,
J. E. Rossi,
A. Voloschin,
J. Baehring,
H. Shimazaki,
R. Koide,
D. King,
...
W. Mason,
L. Sansing,
M. Dichter,
M. Rosenfeld,
D. Lynch
|
11 |
2007 |
11
🐜
|
|
🐜
|
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
14 auth.
O. Chinot,
W. Wick,
W. Mason,
R. Henriksson,
F. Saran,
R. Nishikawa,
A. Carpentier,
K. Hoang-Xuan,
P. Kavan,
D. Cernea,
...
A. Brandes,
M. Hilton,
L. Abrey,
T. Cloughesy
|
11 |
2014 |
11
🐜
|
|
🐢
|
Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
28 auth.
J. Perry,
N. Laperriere,
C. O'Callaghan,
A. Brandes,
J. Menten,
C. Phillips,
M. Fay,
R. Nishikawa,
G. Cairncross,
W. Roa,
D. Osoba,
J. Rossiter,
A. Sahgal,
H. Hirte,
F. Laigle-Donadey,
...
E. Franceschi,
O. Chinot,
V. Golfinopoulos,
L. Fariselli,
A. Wick,
L. Feuvret,
M. Back,
M. Tills,
C. Winch,
B. Baumert,
W. Wick,
K. Ding,
W. Mason
|
9 |
2017 |
9
🐢
|
|
🐬
|
Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma
R. Vitaliani,
W. Mason,
B. Ances,
T. Zwerdling,
Zhilong Jiang,
J. Dalmau
|
9 |
2005 |
9
🐬
|
|
🐜
|
Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies
19 auth.
Mar Petit-Pedrol,
T. Armangué,
Xiaoyu Peng,
L. Bataller,
T. Cellucci,
Rebecca Davis,
Lindsey Mccracken,
E. Martínez-Hernandez,
W. Mason,
M. Kruer,
...
David G. Ritacco,
W. Grisold,
B. Meaney,
C. Alcalá,
P. Sillevis-Smitt,
M. Titulaer,
R. Balice-Gordon,
F. Graus,
J. Dalmau
|
9 |
2014 |
9
🐜
|
|
🐜
|
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
24 auth.
Tracy T. Batchelor,
P. Mulholland,
B. Neyns,
L. Nabors,
M. Campone,
A. Wick,
W. Mason,
T. Mikkelsen,
S. Phuphanich,
L. Ashby,
...
J. Degroot,
R. Gattamaneni,
L. Cher,
M. Rosenthal,
F. Payer,
J. Jürgensmeier,
R. Jain,
A. Sorensen,
John Xu,
Qi Liu,
M. J. van den Bent,
Tracy T. Batchelor,
Stephen E,
C. Pappas
|
8 |
2013 |
8
🐜
|
|
🐜
|
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
13 auth.
W. Wick,
V. Puduvalli,
M. Chamberlain,
M. J. van den Bent,
A. Carpentier,
L. Cher,
W. Mason,
M. Weller,
Shengyan Hong,
L. Musib,
...
A. Liepa,
D. Thornton,
H. Fine
|
8 |
2010 |
8
🐜
|
|
🐜
|
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
14 auth.
R. Mirimanoff,
T. Gorlia,
W. Mason,
M. J. van den Bent,
R. Kortmann,
B. Fisher,
M. Reni,
A. Brandes,
J. Curschmann,
S. Villà,
...
G. Cairncross,
A. Allgeier,
D. Lacombe,
R. Stupp
|
8 |
2006 |
8
🐜
|
|
🐜
|
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
7 auth.
R. Stupp,
M. Hegi,
M. J. van den Bent,
W. Mason,
M. Weller,
R. Mirimanoff,
...
J. Cairncross
|
8 |
2006 |
8
🐜
|
|
🐜
|
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma
37 auth.
B. Baumert,
M. Hegi,
M. J. van den Bent,
A. von Deimling,
T. Gorlia,
K. Hoang-Xuan,
A. Brandes,
G. Kantor,
M. Taphoorn,
M. Hassel,
C. Hartmann,
G. Ryan,
D. Capper,
J. Kros,
S. Kurscheid,
...
W. Wick,
R. Enting,
M. Reni,
B. Thiessen,
F. Dhermain,
J. Bromberg,
L. Feuvret,
J. Reijneveld,
O. Chinot,
J. Gijtenbeek,
J. Rossiter,
N. Dif,
C. Balañà,
J. Bravo-Marques,
P. Clement,
C. Marosi,
T. Tzuk-Shina,
R. Nordal,
J. Rees,
D. Lacombe,
W. Mason,
R. Stupp
|
8 |
2016 |
8
🐜
|
|
🐜
|
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
13 auth.
J. Perry,
K. Bélanger,
W. Mason,
D. Fulton,
P. Kavan,
J. Easaw,
C. Shields,
S. Kirby,
D. Macdonald,
D. Eisenstat,
...
B. Thiessen,
P. Forsyth,
J. Pouliot
|
8 |
2010 |
8
🐜
|
|
🐜
|
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.
14 auth.
F. Graus,
J. Dalmou,
R. Reñé,
M. Torà,
N. Malats,
J. Verschuuren,
F. Cardenal,
N. Viñolas,
J. G. Muro,
C. Vadell,
...
W. Mason,
R. Rosell,
J. Posner,
F. Real
|
8 |
1997 |
8
🐜
|
